A targetable N-terminal motif orchestrates α-Synuclein oligomer to fibril conversion

Jaime Santos,Jorge Cuellar,Irantzu Pallarès,Emily J Byrd,Alons Lends,Fernando Moro,Muhammed Bilal Abdul-Shukkoor,Jordi Pujols,Lorea Velasco-Carneros,Frank Sobott,Daniel E Otzen,Antonio N Calabrese,Arturo Muga,Jan S Pedersen,Antoine Loquet,Jose María Valpuesta,Sheena E Radford,Salvador Ventura
DOI: https://doi.org/10.1101/2023.02.10.527650
2024-02-14
Abstract:Oligomeric species populated during α-synuclein aggregation are considered key drivers of neurodegeneration in Parkinson’s disease. However, the development of oligomer-targeting therapeutics is constrained by our limited knowledge of their structure and the molecular determinants driving their conversion to fibrils. PSMα3 is a nanomolar peptide binder of α-synuclein oligomers that inhibits aggregation by blocking oligomer to fibril conversion. Here, we investigate the binding of PSMα3 to α-synuclein oligomers to discover the mechanistic basis of this protective activity. We find that PSMα3 selectively targets an α-synuclein N-terminal motif (residues 36-61) that populates a distinct conformation in the monomeric and oligomeric states. This α-synuclein region plays a pivotal role in oligomer to fibril conversion, as its absence renders the central NAC domain insufficient to prompt this structural transition. The hereditary mutation G51D, associated with early-onset Parkinson’s disease, causes a conformational fluctuation in this region, leading to delayed oligomer to fibril conversion and an accumulation of oligomers that are resistant to remodeling by molecular chaperones. Overall, our findings unveil a new targetable region in α-synuclein oligomers, advance our comprehension of oligomer to amyloid fibril conversion and reveal a new facet of α-synuclein pathogenic mutations.
Biophysics
What problem does this paper attempt to address?